Extended-release tacrolimus in stable child liver transplant recipients
This study tests an extended-release version of the anti-rejection drug tacrolimus in children who have already had a stable liver transplant. The goal is to see if the longer-acting capsule works as well as the immediate-release form, potentially simplifying daily medication routines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 18 years old or younger and has had a liver transplant.
- Your child can swallow capsules whole.
- Your child has been taking the immediate-release form of tacrolimus for at least 3 months.
- Blood counts, liver and kidney function, and blood clotting are normal, and doctors consider your child stable.
- Your child is scheduled for a planned liver biopsy as part of this study.
- Your child is not allergic to tacrolimus and has not taken the extended-release form before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
This study looks at whether it is safe to stop or reduce anti-rejection medicines in children who have had a liver transplant for at least 4 years and are doing well. The goal is to see if they can live without these medicines and their side effects.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.